Five distinct Epstein-Barr virus (EBV)-deterinned nuclear antigens (EBNA-1 to were recently identified. Antibody responses to these antigens could conceivably differ, and thus prove of serodiagnostic value, in EBVassociated disease processes. As a rst step, murine or human cell lines transfected with appropriate EBV DNA fragments and stably expressing either EBNA-1 or EBNA-2 were used to determine the frequency and time of emergence of antibodies to these two antigens in the course of acute and chronic infectious mononucleosis (IM) and to assess their titers in so-called chronic active EBV infections. Following IM, pntibodies to EBNA-2 arose first and, after reaching peak titers, declined again in time to lower persistent or even nondetectable levels. Antibodies to EBNA-1 emerged several weeks or months after anti-EBNA-2 and gradually attained the titers at which they persisted indefinitely. The ratios between the anti-EBNA-1 and anti-EBNA-2 titers therefore were generally well below 1.0 during the first 6-12 months after IM and turned to well above 1.0 during the second year. In clear cases of chronic IM, the inversion of this ratio was delayed or prevented. In the less well-defined chronic EBV infections, low ratios were observed in only some of the patients. Because many of these illnesses were not ushered in by a proven IM and often showed EBV-specific antibody profiles within the normally expected range, a causal role of the virus in these cases remains doubtful.
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Epstein-Barr virus (EBV)-encoded antigens are divided into those associated with the viral replicative cycle [i.e., the viral capsid antigen (VCA) and the early antigens (EA) of the diffuse (D) and restricted (R) varieties] and those expressed in latently infected B lymphocytes, the EBV-determined nuclear antigen (EBNA) (1) . Both categories contain, in addition, distinct EBV-induced cell membrane antigens. Antibodies to VCA and the EA components emerge during the late incubation period or in the course of the acute phase of infectious mononucleosis (IM), whereas antibodies to EBNA arise only weeks or months after onset of the disease, indicating that the two sets of antigens become available for stimulation of antibody responses from separate sets of cells under different circumstances (2 EBNA is now known to be a complex of several antigens. First EBNA-1 and EBNA-2 were separated (4-8), followed by EBNA-3 (9) (10) (11) , and most recently EBNA-4 (11) and EBNA-5 (12) . EBNA-1 appears to be required for maintenance of the virus in episomal form (13 (20) (21) (22) (23) (24) (25) . Some of the IM patients had participated in open or double-blind placebocontrolled studies on the effectiveness of tinidazole or acyclovir therapy, respectively. The sera of patients with chronic IM-like illnesses were derived mainly from an ongoing study carried out at the National Institutes of Health, some of whom were previously described (26) . The chronic illnesses were characterized by various degrees of fatigue, malaise, lymphadenopathy, sore throat, and other constitutional symptoms. For the present analysis, these patients were divided into three groups. Group 1 comprises patients who in the wake of a confirmed IM developed numerous successive, often life-threatening, complications over the course of many years accompanied by excessively high IgG antibody titers to VCA and to D (_1:10,240) and often also high titers of IgA antibodies to these antigens, whereas antibodies to EBNA remained at normal or subnormal levels (27, 28) . There is little doubt that EBV caused these rare cases. Group 2 includes patients whose chronic illnesses were ushered in by a proven IM in only some but by no means all cases. Their IgG antibody titers to VCA were elevated (1:640 to 1:5120) and their anti-EA titers, directed mostly against R, rarely against D, ranged from 1:80 to 1:640, but the anti-EBNA levels were moderate or nondetectable. Group 3, by far the largest, is clinically indistinguishable from group 2. The EBV-specific antibody profiles of these patients remained well within the range normally expected years after a primary EBV infection, except that a few lacked antibodies to EBNA. Data supporting an association of EBV with the illnesses of the patients in groups 2 and 3 are not compelling, but elevated antibody titers render such an association for group 2 more likely than for group 3. That other causes for these chronic complaints exist became clearly evident from a small fourth group of patients who had similar complaints as the patients in groups 2 and 3 but were as yet EBV seronegative (unpublished observations).
EBV-Specific Serology. Antibodies to VCA, D, and R were determined by indirect immunofluorescence and antibodies to EBNA by anti-complement immunofluorescence as described (29, 30 (12) and BJAB cells containing none of them served as positive and negative controls, respectively. Raji, BJAB, and DG75/pEAA6 cells do not attach to the culture vessels, but the 3T3/pBK cells grow attached to glass or plastic. They were dislodged by trypsin (0.25%) and washed before cell smears were made in the same manner as described elsewhere in detail for lymphoblastoid cells (31) . Care was taken to obtain near monolayers and to prevent piling up of the cells by spreading a small drop containing =3 x 105 cells over 6 x 30 mm coverslips. The smears were allowed to dry rapidly in the air current of a laminar flow hood and, when seemingly dry, were kept for 2 hr at room temperature before being fixed for 5 min in a precooled (-20°C) equal mixture of acetone and methanol. After fixation, the smears were kept in plastic boxes at -20°C until used.
RESULTS
Anti-EBNA-T and Anti-EBNA-2 Responses in IM. Fig. 1 and Table 1 present the EBV-specific serologic results obtained with serial sera from numerous IM patients. The diagnosis was confirmed in each case by demonstration of IgM antibodies to VCA and initial absence of antibodies to EBNA, by the detection of IM-specific heterophil antibodies in nearly all, and by the presence of antibodies to the D component of the EA complex in =80% of the patients. The sera are grouped according to the time they were collected after onset of disease or admission to inpatient or outpatient services. Each dot in the figure presents the results obtained with a given serum, the anti-EBNA-1 titer being found on the abscissa and the anti-EBNA-2 titer on the ordinate. Practically all EBNA-specific antibodies that were detected by the use of Raji cell smears within the first 3 months were directed against EBNA-2. Nearly 75% of the sera collected during this period still revealed VCA-specific IgM at titers ranging from 1:10 to 1:80 (Table 1) ; anti-D was detected in =60% as the sole antibody to the EA complex or it was exceeded in titer or replaced by anti-R so that almost one-half of the patients showed antibodies to R. The next group of sera, collected mainly 6 and 12 months after onset of IM, revealed the emergence in the majority of the patients of low levels of antibodies to EBNA-1 that in most instances were exceeded Fig. 2 presents the anti-EBNA-1 and anti-EBNA-2 titers of the three seropositive groups of patients described in Materials and Methods. The chronic IM patients in group 1 with excessively high anti-VCA and anti-D titers (Fig. 2 Lower) had, with a single exception, anti-EBNA-2 titers that equalled or exceeded the anti-EBNA-1 levels (Fig. 2 Upper) . Three of these patients, in fact, had no detectable anti-EBNA-1, as noted earlier (28, 32) . The patients with less well-defined illnesses in groups 2 and 3 had, with rare exceptions, antibodies to both EBNA-1 and EBNA-2, but the anti-EBNA-2 titers were found to be equal to or higher than the anti-EBNA-1 titers in 23% and 30% of the cases, respectively. Only 2 of the 69 patients lacked antibodies to EBNA-1 and four lacked antibodies to EBNA-2. All healthy seropositive controls in this particular series had antibodies to EBNA-1, but nearly 30% lacked detectable antibodies to EBNA-2 and in none did the titer of anti-EBNA-2 equal or exceed the titer of anti-EBNA-1. These results suggest that, in some cases of chronic active IM or IM-like illnesses, the change from dominant anti-EBNA-2 to dominant anti-EBNA-1 may be delayed or prevented.
Efforts to correlate the individual titers or ratios between antibody titers to EBNA-1 and EBNA-2 to the past history and persisting signs and symptoms of the patients in groups 2 or 3 were unsuccessful. There were no clear associations between duration or nature of illnesses, anti-EA titers, or history of IM with the results of the anti-EBNA-1 or anti-EBNA-2 tests.
DISCUSSION
The results have shown that the sum total of anti-EBNA titers obtained with Raji cell smears is always closely matched by either the anti-EBNA-1 or the anti-EBNA-2 titer depending on which of the two is dominant. Antibodies to the other EBNA components thus may normally fail to affect the overall anti-EBNA titer.
While this manuscript was in preparation, a report was published showing that antibodies to EBNA-1 appeared long after anti-EBNA had become detectable by the use of Raji cell smears (33) . As shown here, the antibody production to EBNA-1 and to EBNA-2 in the course of IM appears to be subject to an orderly progression. Anti-EBNA-2 emerges first, reaches peak titers, and then declines to a lower persistent level or even becomes nondetectable in about one-third of the cases. Anti-EBNA-1 arises long after anti-EBNA-2, increases gradually in titer to exceed in time the level of anti-EBNA-2, and then persists indefinitely at the ultimately attained plateau. Thus, within the first year after IM, the ratio between the anti-EBNA-1 and anti-EBNA-2 titers is usually well below 1.0, whereas later the ratio turns generally to well above 1. excessively high antibody titers to VCA and to D (27, 28) . All but one of the patients in this category either lacked antibodies to EBNA-1, as noted earlier (32) , or showed dominant anti-EBNA-2 titers. Thus, demonstration of anti-EBNA-1/anti-EBNA-2 ratios of <1.0 more than 2 years after onset of IM indicates a defective control of the persistent latent EBV carrier state that regularly ensues after primary EBV infections. Also, some of the patients in groups 2 and 3 who suffered from less well-defined so-called chronic active EBV infections (26, 34, 35) showed an anti-EBNA-1/anti-EBNA-2 ratio of <1.0. Because some of these illnesses were not ushered in by a bonafide IM, a ratio of <1.0 might not have been due to an arrest in the progression of the early immune responses but rather the result of an activation of the latent persistent viral carrier state by some immunosuppressive event-e.g., another infectious disease. The subset of patients with Hodgkin disease or non-Hodgkin lymphomas who develop unusually high antibody titers to VCA and to D or R (36) or patients with the acquired immunodeficiency syndrome or genetic immune defects show indeed a high incidence of anti-EBNA-1/anti-EBNA-2 ratios below 1.0 (unpublished data). Attempts to correlate low ratios among the patients of groups 2 and 3 with specific clinical observations failed to meet with success.
The question why antibodies to EBNA-2 emerge well ahead of anti-EBNA-1 cannot be answered at present. Obvious explanations would be that EBNA-2 is produced earlier, or in larger amounts, or is a more potent antigen than EBNA-1. Both antigens appear, however, almost simultaneously in EBV-transformed B lymphocytes and are synthesized in seemingly comparable quantities, judging by the degrees of immunofluorescence they yield or by immune blot analysis (11, 13, 37) . It is unknown, though, whether and in what amounts EBNA components are synthesized in oropharyngeal epithelial cells, which are thought to be the initial targets of the virus in primary EBV infections (38) . The assumption that EBNA-2 is a more potent antigen than EBNA-1 also offers an unresolved problem. Why should production of antibodies to EBNA-2 decline or even cease in time, whereas antibodies to the "weaker" EBNA-1 ultimately become dominant and persist? Could this be a matter of a difference in presentation of the antigens early in the course of a primary EBV infection, when a large number of B lymphocytes are growth transformed, as compared to later when only a few such cells circulate? These problems may be resolved only after successful cultivation of the appropriate fully permissive target cells involved in the primary EBV infection to permit detailed study of the temporal and quantitative aspects of the emergence of various antigens after exposure to the virus.
